Status | Study |
Not yet recruiting |
Study Name: Daratumumab in Treatment of PGNIMD and C3 GN Condition: Membranoproliferative Glomerulonephritis Date: 2017-03-20 Interventions: Drug: Daratumumab Open-label Other Name: Darzalex |
Recruiting |
Study Name: Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy Condition: Glomerulonephritis, Membranous Date: 2017-01-09 Interventions: Drug: Rituximab Rituximab,1 g |
Not yet recruiting |
Study Name: Immunoadsorption in Anti-GBM Glomerulonephritis. Condition: Anti-glomerular Basement Membrane Glomerulonephritis Date: 2016-05-03 Interventions: Device: Immunoadsorption (Immunosorba) |
Completed |
Study Name: Recurrent Glomerulonephritis After Renal Transplantation Condition: Glomerulonephritis Date: 2016-02-25 |
Recruiting |
Study Name: ACE-inhibitors in Extracapillary Glomerulonephritis Condition: Extracapillary Glomerulonephritis Date: 2016-02-10 Interventions: Drug: Lisinopril |
Completed |
Study Name: Autonomic Nervous System (ANS) and Renal Function in Immunoglobin A (IgA) Nephropathy Condition: IGA Glomerulonephritis Date: 2015-08-18 Interventions: Device: Holter measure of ANS in IgAN patients |
Active, not recruiting |
Study Name: Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis Condition: Fibrillary Glomerulonephritis Date: 2014-07-21 Interventions: Drug: rituximab After successful enrollment, patients will be treated with an infusion dose of rituximab |
Active, not recruiting |
Study Name: Eculizumab in Primary MPGN Condition: Membranoproliferative Glomerulonephritis Date: 2014-03-17 Interventions: Drug: Eculizumab Other Name: Soliris |
Recruiting |
Study Name: Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis Condition: Glomerulonephritis Proteinuria Date: 2014-02-12 Interventions: Drug: Shenyankangfu tablets Sh |
Completed |
Study Name: A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy Condition: Glomerulonephritis, Membranous Date: 2012-05-31 Interventions: Drug: belimumab 10mg/kg administered intravenously |